1. ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT‐402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) Authors: Radford, J.; Kahl, B.; Hamadani, M.; Carlo‐Stella, C.; O'Connor, O.A.; Ardeshna, K.M.; Feingold, J.; He, S.; Reid, E.; Solh, M.; Chung, K.; Heffner, L.; Ungar, D.; Caimi, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 93 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) Authors: Dalovisio, A.; Bahlis, N.; Raje, N.; Costello, C.; Dholaria, B.; Solh, M.; Levy, M.; Tomasson, M.; Dube, H.; Damore, M.; Jiang, S.; Basu, C.; Skoura, A.; Chan, E.; Trudel, S.; Jakubowiak, A.; Chu, M.; Gasparetto, C.; Sebag, M.; Lesokhin, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 788 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗